Video

Dr. Flaig on Immune Checkpoint Inhibitors in Advanced Bladder Cancer

Thomas W. Flaig, MD, discusses the utility of immune checkpoint inhibitors in advanced bladder cancer.

Thomas W. Flaig, MD, professor, associate dean for clinical research, Genitourinary Cancer Program, Division of Medical Oncology, University of Colorado, Denver, discusses the utility of immune checkpoint inhibitors in advanced bladder cancer.

Five checkpoint inhibitors, nivolumab (Opdivo), atezolizumab (Tecentriq), pembrolizumab (Keytruda), durvalumab (Imfinzi), and avelumab (Bavencio), are approved for patients with advanced bladder cancer.

Although this new class of drugs has revolutionized the space, single-agent checkpoint inhibitors elicit response rates of around 20% to 25%, explains Flaig. Combination strategies may increase response rates while maintaining durability and tolerability.

In terms of treatment, the majority of patients with advanced disease should receive up front chemotherapy followed by an immune checkpoint inhibitor in the second-line setting.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity